Telesis Bio (OTCMKTS:TBIO – Get Free Report) is expected to be issuing its resultson Tuesday, November 17th. Analysts expect the company to announce earnings of ($6.39) per share and revenue of $2.53 million for the quarter.
Telesis Bio Stock Performance
TBIO opened at $0.01 on Tuesday. Telesis Bio has a 12 month low of $0.00 and a 12 month high of $0.15. The business has a 50-day moving average of $0.01 and a two-hundred day moving average of $0.03.
About Telesis Bio
Telesis Bio, Inc develops automated synthetic biology systems designed to help researchers create and test biological molecules more efficiently. Its technology is intended to streamline the design-build-test process by automating tasks that traditionally require multiple manual laboratory steps.
The company’s primary products include the BioXp automated benchtop platforms and related consumables, software, and application-specific kits. These systems support the on-demand synthesis and assembly of DNA, messenger RNA and other biological constructs for applications such as gene and cell therapy research, vaccine development, protein engineering, diagnostics and synthetic biology.
Telesis Bio was formerly known as Codex DNA and changed its corporate name in 2023.
Read More
- Five stocks we like better than Telesis Bio
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for Telesis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Telesis Bio and related companies with MarketBeat.com's FREE daily email newsletter.
